UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Microfluidics and Circulating Tumor Cells

The Journal of molecular diagnostics : JMD, 2013-03, Vol.15 (2), p.149-157

2013

Volltextzugriff (PDF)

Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases

Science signaling, 2010-08, Vol.3 (136), p.ra64

2010

Volltextzugriff (PDF)

Profiling of UV-induced ATM/ATR signaling pathways

Proceedings of the National Academy of Sciences - PNAS, 2007-12, Vol.104 (50), p.19855-19860

2007

Volltextzugriff (PDF)

Effect of FAK inhibitor defactinib on tumor immune changes and tumor reductions in a phase II window of opportunity study in malignant pleural mesothelioma (MPM)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.8555-8555

2017

Volltextzugriff (PDF)

DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancer

PloS one, 2014-07, Vol.9 (7), p.e102112

2014

Volltextzugriff (PDF)

Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer

Human pathology, 2012-09, Vol.43 (9), p.1363-1375

2012

Volltextzugriff (PDF)

Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKε promotes cell transformation

Molecular cell, 2009-05, Vol.34 (4), p.461-472

2009

Volltextzugriff (PDF)

Cytogenetic and Molecular Marker Associations to Outcomes with Duvelisib and Ofatumumab Treatment in Patients with Relapsed or Refractory CLL/SLL in the DUO Trial

Blood, 2019-11, Vol.134 (Supplement_1), p.4312-4312

2019

Volltextzugriff (PDF)

INSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with KIT exon 11 + 17/18 mutations

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.TPS767-TPS767

2024

Volltextzugriff (PDF)

INSIGHT: A phase 3, randomized, multicenter, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib harboring KIT exon 11 + 17 and/or 18 mutations

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS11582-TPS11582

2023

Volltextzugriff (PDF)

Mutational heterogeneity of imatinib resistance and efficacy of ripretinib vs sunitinib in patients with gastrointestinal stromal tumor: ctDNA analysis from INTRIGUE

Journal of clinical oncology, 2023-04, Vol.41 (36_suppl), p.397784-397784

2023

Volltextzugriff (PDF)

A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) (TEMPO)

Blood, 2019-11, Vol.134 (Supplement_1), p.5251-5251

2019

Volltextzugriff (PDF)

Decreased activity and enhanced nuclear export of CCAAT-enhancer-binding protein beta during inhibition of adipogenesis by ceramide

Biochemical journal, 2002-07, Vol.365 (Pt 1), p.181-191

2002

Volltextzugriff (PDF)

Outcomes in patients with advanced gastrointestinal stromal tumor who did not have baseline ctDNA detected in the INTRIGUE study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.11536-11536

2023

Volltextzugriff (PDF)

Characterization and Validation of Antibodies for Immunohistochemical Staining of the Chemokine CXCL12

The journal of histochemistry and cytochemistry, 2019-04, Vol.67 (4), p.257-266

2019

Volltextzugriff (PDF)

The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations

Future oncology (London, England), 2024-09, Vol.20 (27), p.1-1982

2024

Volltextzugriff (PDF)

Abstract 568: FAKPYK2 inhibition enhances immune checkpoint inhibitor efficacy

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.568-568

2016

Volltextzugriff (PDF)

Abstract 568: FAK/PYK2 inhibition enhances immune checkpoint inhibitor efficacy

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.568-568

2016

Volltextzugriff (PDF)

The effect of duvelisib, a dual inhibitor of PI3K-δ,γ, on components of the tumor microenvironment in previously untreated follicular lymphoma

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.7579-7579

2018

Volltextzugriff (PDF)

Abstract 974: FAK inhibitors VS-6063 and VS-4718 target cancer stem cells: Implications for TNBC sequential and combination therapies

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.974-974

2015

Volltextzugriff (PDF)

Prognostic and Immune-Related Factors for Response to Duvelisib in the Phase 2 DYNAMOTM Clinical Trial in iNHL

Blood, 2018-11, Vol.132 (Supplement 1), p.4167-4167

2018

Volltextzugriff (PDF)

Abstract C29: FAK inhibition targets cancer stem cells

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.C29-C29

2015

Volltextzugriff (PDF)

Phosphorylation of the Tumor Suppressor CYLD by the Breast Cancer Oncogene IKKɛ Promotes Cell Transformation

Molecular cell, 2009-05, Vol.34 (4), p.461-472

2009

Volltextzugriff (PDF)

Abstract 613: X4P-001, an orally bioavailable CXCR4 antagonist, enhances immune cell infiltration and activation in the tumor microenvironment of melanoma

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.613-613

2018

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(40)
Dissertationen
(1)

Sprache

Englisch
(41)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Microfluidics and Circulating Tumor Cells

Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases

Profiling of UV-induced ATM/ATR signaling pathways

Effect of FAK inhibitor defactinib on tumor immune changes and tumor reductions in a phase II window of opportunity study in malignant pleural mesothelioma (MPM)

DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancer

Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer

Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKε promotes cell transformation

Cytogenetic and Molecular Marker Associations to Outcomes with Duvelisib and Ofatumumab Treatment in Patients with Relapsed or Refractory CLL/SLL in the DUO Trial

INSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with KIT exon 11 + 17/18 mutations

INSIGHT: A phase 3, randomized, multicenter, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib harboring KIT exon 11 + 17 and/or 18 mutations

Mutational heterogeneity of imatinib resistance and efficacy of ripretinib vs sunitinib in patients with gastrointestinal stromal tumor: ctDNA analysis from INTRIGUE

A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) (TEMPO)

Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial

Decreased activity and enhanced nuclear export of CCAAT-enhancer-binding protein beta during inhibition of adipogenesis by ceramide

Outcomes in patients with advanced gastrointestinal stromal tumor who did not have baseline ctDNA detected in the INTRIGUE study

Characterization and Validation of Antibodies for Immunohistochemical Staining of the Chemokine CXCL12

The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations

Abstract 568: FAKPYK2 inhibition enhances immune checkpoint inhibitor efficacy

Abstract 568: FAK/PYK2 inhibition enhances immune checkpoint inhibitor efficacy

The effect of duvelisib, a dual inhibitor of PI3K-δ,γ, on components of the tumor microenvironment in previously untreated follicular lymphoma

Abstract 974: FAK inhibitors VS-6063 and VS-4718 target cancer stem cells: Implications for TNBC sequential and combination therapies

Prognostic and Immune-Related Factors for Response to Duvelisib in the Phase 2 DYNAMOTM Clinical Trial in iNHL

Abstract C29: FAK inhibition targets cancer stem cells

Phosphorylation of the Tumor Suppressor CYLD by the Breast Cancer Oncogene IKKɛ Promotes Cell Transformation

Abstract 613: X4P-001, an orally bioavailable CXCR4 antagonist, enhances immune cell infiltration and activation in the tumor microenvironment of melanoma

Suchergebnisse filtern